IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN)
Expanded access is no longer available for this treatment.
Sponsor:
Bayer
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01538680
First received: February 21, 2012
Last updated: June 11, 2017
Last verified: June 2017
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | Expanded access is no longer available for this treatment. |
|---|---|
| Study Completion Date: | No date given |
| Primary Completion Date: | No date given |